drugset / Trial / NCT04351932

Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

NCT04351932

RandomizedParallel-groupOpen-labelTreatment

Summary

Mesenchymal stem cells (MSC) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as umbilical cord, bone marrow, and adipose tissue. The multipotent properties of MSCs make them a promising option for the treatment of osteoarthritis (OA). Bone marrow mesenchymal stem cells (BM-MSC) and adipose derived mesenchymal stem cells (AD-MSC) have been used separately to treat OA. The aim of the present study will be to compare in a randomized non blind controlled clinical trial 3 types of intra-articular injections containing MSC populations obtained from two clinically relevant sources: BM-MSC, AD-MSC and a combination of both BM-MSC and AD-MSC.

Timeline

Start
2020-06-07
Primary completion
2021-06-07
Completion
2021-09-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bone marrow mesenchymal stem cells Cell therapy 5 ml Other
Comparator Bone marrow mesenchymal stem cells Cell therapy 10 ml Other
Comparator adipose mesenchymal stem cells Cell therapy 5 ml Other
Comparator adipose mesenchymal stem cells Cell therapy 10 ml Other

Indications